



## **TRACON Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference**

March 21, 2018

SAN DIEGO, March 21, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration, announced today that Charles Theuer, M.D., Ph.D., President and CEO, will present a corporate update at the 17<sup>th</sup> Annual Needham Healthcare Conference at 2:30 pm EDT on Wednesday, March 28, 2018, at the Westin Grand Central Hotel in New York, NY.

To access a live webcast of the presentation, please visit the "Events and Presentation" section within the "Investors" section of the TRACON Pharmaceuticals website at [www.traconpharma.com](http://www.traconpharma.com). A replay of the webcast will be available on the website for 60 days following the event.

### **About TRACON**

TRACON develops targeted therapies for cancer and ophthalmic diseases. The Company's clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; TRC102, a small molecule being developed for the treatment of lung cancer and glioblastoma; and TRC253, a small molecule being developed for the treatment of prostate cancer. To learn more about TRACON and its product candidates, visit TRACON's website at [www.traconpharma.com](http://www.traconpharma.com).

Company Contact:	Investor Contact:
Patricia Bitar	Andrew McDonald
Chief Financial Officer	LifeSci Advisors LLC
(858) 550-0780 ext. 223	646-597-6987
<a href="mailto:pbitar@traconpharma.com">pbitar@traconpharma.com</a>	<a href="mailto:Andrew@lifesciadvisors.com">Andrew@lifesciadvisors.com</a>

 [Primary Logo](#)

Source: TRACON Pharmaceuticals, Inc.